^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Vessey DA, Lau E, Kelley M, Warren RS (Mar 2003). "Isolation, sequencing, and expression of a cDNA for the HXM-A form of xenobiotic/medium-chain fatty acid:CoA ligase from human liver mitochondria". J Biochem Mol Toxicol. 17 (1): 1–6. doi:10.1002/jbt.10056. PMID12616642. S2CID13396633.
Lindner I, Rubin D, Helwig U, et al. (2006). "The L513S polymorphism in medium-chain acyl-CoA synthetase 2 (MACS2) is associated with risk factors of the metabolic syndrome in a Caucasian study population". Mol Nutr Food Res. 50 (3): 270–4. doi:10.1002/mnfr.200500241. PMID16521160.
Vessey DA, Kelley M, Warren RS (2004). "Characterization of triacsin C inhibition of short-, medium-, and long-chain fatty acid: CoA ligases of human liver". J. Biochem. Mol. Toxicol. 18 (2): 100–6. doi:10.1002/jbt.20009. PMID15122652. S2CID8154380.
Vessey DA, Kelley M, Warren RS (1999). "Characterization of the CoA ligases of human liver mitochondria catalyzing the activation of short- and medium-chain fatty acids and xenobiotic carboxylic acids". Biochim. Biophys. Acta. 1428 (2–3): 455–62. doi:10.1016/s0304-4165(99)00088-4. PMID10434065.
Vessey DA, Hu J (1997). "Isolation from bovine liver mitochondria and characterization of three distinct carboxylic acid: CoA ligases with activity toward xenobiotics". J. Biochem. Toxicol. 10 (6): 329–37. doi:10.1002/jbt.2570100608. PMID8934636.